Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant

被引：6

作者：

Brunvand, Mark W. ^{[1
]}

Bitter, Mitchell ^{[2
]}

机构：

[1] Rocky Mt Blood & Marrow Transplant Program, Denver, CO 80218 USA

[2] Unipath, Denver, CO USA

来源：

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷 / 03期

关键词：

SYSTEMIC AL AMYLOIDOSIS; CHEMOTHERAPY; SURVIVAL;

D O I：

10.3324/haematol.2009.013102

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：519 / 521

页数：3

共 11 条

[1]

Comenzo RL, 2007, CONTRIB NEPHROL, V153, P195

[2] Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study [J].

Dispenzieri, A ;

Kyle, RA ;

Lacy, MQ ;

Therneau, TM ;

Larson, DR ;

Plevak, MF ;

Rajkumar, SV ;

Fonseca, R ;

Greipp, PR ;

Witzig, TE ;

Lust, JA ;

Zeldenrust, SR ;

Snow, DS ;

Hayman, SR ;

Litzow, MR ;

Gastineau, DA ;

Tefferi, A ;

Inwards, DJ ;

Micallef, IN ;

Ansell, SM ;

Porrata, LF ;

Elliott, MA ;

Gertz, MA .

BLOOD, 2004, 103 (10) :3960-3963

[3] Myeloablative chemotherapy with stem cell rescue for the treatment of primary systemic amyloidosis: a status report [J].

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A .

BONE MARROW TRANSPLANTATION, 2000, 25 (05) :465-470

[4] Transplantation for amyloidosis [J].

Gertz, Morie A. ;

Lacy, Martha Q. ;

Dispenzieri, Angela ;

Hayman, Suzanne R. ;

Kumar, Shaji .

CURRENT OPINION IN ONCOLOGY, 2007, 19 (02) :136-141

[5] Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy [J].

Lachmann, HJ ;

Gallimore, R ;

Gillmore, JD ;

Carr-Smith, HD ;

Bradwell, AR ;

Pepys, MB ;

Hawkins, PN .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (01) :78-84

[6] Molecular mechanisms of amyloidosis [J].

Merlini, G ;

Bellotti, V .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06) :583-596

[7] Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients [J].

Moreau, P ;

Leblond, V ;

Bourquelot, P ;

Facon, T ;

Huynh, A ;

Caillot, D ;

Hermine, O ;

Attal, M ;

Hamidou, M ;

Nedellec, G ;

Ferrant, A ;

Audhuy, B ;

Bataille, R ;

Milpied, N ;

Harousseau, JL .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (04) :766-769

[8] Bortezomib in the front-line treatment of multiple myeloma [J].

Richardson, Paul G. ;

Mitsiades, Constantine ;

Schlossman, Robert ;

Ghobrial, Irene ;

Hideshima, Teru ;

Munshi, Nikhil ;

Anderson, Kenneth C. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) :1053-1072

[9] Long-term outcome-of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation [J].

Sanchorawala, Vaishali ;

Skinner, Martha ;

Quillen, Karen ;

Finn, Kathleen T. ;

Doros, Gheorghe ;

Seldin, David C. .

BLOOD, 2007, 110 (10) :3561-3563

[10] Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease [J].

Wechalekar, Ashutosh D. ;

Lachmann, Helen J. ;

Offer, Mark ;

Hawkins, Philip N. ;

Gillmore, Julian D. .

HAEMATOLOGICA, 2008, 93 (02) :295-298

← 1 2 →